Inflarx N.V. revenue

Inflarx N.V.'s revenue was $33,162 in fiscal 2025, down 81.5% on the year before.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inflarx N.V.: revenue history, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	68	179	33
Growth on the year before	—	+162.9%	−81.5%
Gross profit	−507	−3,410	−8,184

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Inflarx N.V.	$33,162	-81.5%	—
Lyell Immunopharma, Inc.	$27,000	-55.0%	-91.8%
AIM Immunotech Inc.	$95,000	-21.5%	-17.3%
Ibio, Inc.	$100,000	-75.0%	-62.4%
Lisata Therapeutics, Inc.	$100,000	-90.7%	—
Celldex Therapeutics, Inc.	$158,000	-97.3%	-63.5%

Compare with peers

Head to head: IFRX vs LYEL AIM vs IFRX IBIO vs IFRX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inflarx N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inflarx N.V.